2M BioTech (Claria Bioscience)

2M Biotech is a family office investment vehicle founded in 29 and based in Dallas Texas. The firm manages an evergreen structure and is looking to make equity investments into companies ranging from $.5 ? $5 million with a preference for the middle of that range. The firm is also willing to co-invest with investors they either know well or are able to get a strong reference for. The firm looks to invest in Seed and Series A rounds and looks to take a significant stake in the company?s equity. The firm prefers to invest in companies that are not located in an areas highly saturated with venture capital. The firm plans to make 3-4 new investments over the next 12 months.
Melissa Krauth
Principal 

AdvaMed United States

The Advanced Medical Technology Association (AdvaMed), is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and health information systems. AdvaMed members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 40 percent purchased annually around the world. AdvaMed's member companies range from the largest to the smallest medical technology innovators and companies.

AdvaMed 2015 - October 5-7, San Diego - is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy-makers, business executives and media, AdvaMed 2015 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more. It is a “must-attend” event for any MedTech company.

Service Provider Type
Sector Interest
Medtech Phase of Development
Unique Capabilities

AdvaMed 2015 is the place where medical technology leaders meet for business development and investment opportunities.  Emerging medical technology companies connect with top industry decision-makers at AdvaMed 2015 to explore strategic business development and capital formation.

Corporate business development professionals and investors will:

  • Discover the latest medical technologies and innovations during the Innovation Showcase and the MedTech Innovator competition;
  • Gain insights into the key investment issues and industry trends during the Funding Forums and Business Development & Finance Panels.

Innovators and early-stage companies will:

  • Learn how to develop an actionable strategic plan in the Entrepreneurship Boot Camp;
  • Pitch their technologies to investors during the Innovations Showcase and explore strategic business development opportunities through MedTech Partnering.
Patrick Brennan
Ray Briscuso
Ashley McMaster
Associate Vice President, Membership and Business Development 
Ashley (Wallin) Wittorf
Executive Director, Emerging Growth Company Council 

Aisling Capital

Aisling Capital is a private equity group based in New York with over $1.6 billion in assets under management. Aisling is currently looking for new firms for potential investments for the firm?s third fund. The firm looks to make investments in companies seeking to raise a total round of $2-5 million. The firm looks to invest in companies globally with a focus on companies located in the United States.
Dennis Purcell
Founder and Senior Advisor 

ALIAD France

ALIAD is the venture capital subsidiary of the Air Liquide Group (L'Air Liquide S.A.), one of the largest multinational providers of industrial and medical gases and related activities, headquartered in Paris, France. The healthcare division of the Air Liquide Group has been playing a significant role in healthcare with over €2 billion in revenue. 
ALIAD aims to promote the Group’s growth and access to innovations through taking minority stakes in innovative technology start-ups outside the Group. ALIAD can lead or co-invest with other investors. Typical allocations are made in equity and range from €1-10 million. ALIAD is currently seeking new opportunities across a wide geography, including Western Europe, North and South America and Asia.

Greg Fleming
Investment Director 

Apple Tree Partners United States

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

Year Founded
1999
Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Sam Hall
Principal 
Aaron Kantoff
Vice President 

Arcus Ventures United States

Arcus Ventures was founded in 2007 and is based in New York City. Arcus Ventures is currently investing from its second fund, which had a first close of $36m in 2014 and is targeting a raise of $100m. The firm typically invests $2-5 million. Arcus invests primarily in the USA but is also open to considering opportunities in Canada.

Myoung-Ok Kwon
Venture Partner 

ATEM Capital

ATEM Capital manages evergreen Life Sciences investment fund - Health Square Fund (HSF). HSF acts as a consolidator of capital flows from the Emerging Markets and invests into the biotech innovation hubs of the US/Western Europe. HSF's international team combines big-picture business perspective with decades of investment scientific legal portfolio risk management and operational experience. The fund is audited by a Big-4 firm. Our Advisory Board comprises high-caliber entrepreneurs VC veterans and seasoned Wall Street professionals.
Alexey Afanasiev
Executive Partner 
Anton Gopka
CEO General Partner 
Elena Ikhsanova
COO General Partner 

Baxter Ventures

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Priyanka Rohatgi
Director 

BioScience Managers Australia

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jeremy Curnock Cook
Managing Director 
Amanda Gillon
Investment Analyst 
Matt McNamara
CIO 

Breakout Labs

Breakout Labs was founded by the Thiel Foundation in 211 and is based in San Francisco CA. Breakout Labs provides seed grants of $35 to 8-1 early stage companies per year. Companies must reach specific milestones in order to receive installments of the grant. Breakout Labs grants are in the form of a convertible note that if the company raises a Series A round will convert based on the Series A valuation, however if the company fails before raising a Series A round no debt will be due. Additionally when a portfolio company becomes revenue-generating or is acquired Breakout Labs receives a 3% royalty payment capped at 3x the value of the grant. Breakout Labs funds companies throughout the USA.
Lindy Fishburne
Executive Director 
Michelle Kim-Danely
Portfolio Manager